Replies to post #189335 on Biotech Values

[DewDiligence]

TEVA reports phase-2/3 data for SD-809 in tardive dyskinesia:

http://finance.yahoo.com/news/teva-advances-pipeline-movement-disorder-120000194.html

SD-809 (deutetrabenazine) is an investigational, oral, small molecule inhibitor of vesicular monoamine 2 transporter, or VMAT2, that is designed to regulate the levels of a specific neurotransmitter, dopamine, in the brain. SD-809 is being developed for the treatment of chorea associated with Huntington’s disease, a neurodegenerative movement disorder that impacts cognition, behavior, and movements. Teva is investigating the broad potential of SD-809 for treating additional movements disorders such as tardive dyskinesia and tics associated with Tourette syndrome.

Teva acquired SD-809 in the ASPX deal (#msg-112224762).

[DewDiligence]

TEVA receives CRL on HD drug acquired from ASPX:

http://finance.yahoo.com/news/teva-receives-complete-response-letter-110000843.html